Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom

OBJECTIVES: The objective of the current preliminary study was to present the cost-effectiveness analyses submitted to the National Institute for Health and Care Excellence (NICE) (TA10765) that deemed semaglutide 2.4 mg subcutaneous (s.c.) injection a cost-effective option for weight management in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandhu, Hera, Xu, Weiwei, Olivieri, Anamaria-Vera, Lübker, Christopher, Smith, Inger, Antavalis, Vasileios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988790/
https://www.ncbi.nlm.nih.gov/pubmed/36630047
http://dx.doi.org/10.1007/s12325-022-02423-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988790/
https://www.ncbi.nlm.nih.gov/pubmed/36630047
http://dx.doi.org/10.1007/s12325-022-02423-8

Ejemplares similares